There is a line in the NHS rulebook that explains most of what is now happening to employer healthcare budgets. Tirzepatide, sold as Mounjaro, is recommended by NICE for managing overweight and obesity only where a patient has a body mass index of at least 35 and at least one weight-related condition, alongside a reduced-calorie diet and more physical activity.
That is a high bar. Everybody below it who wants the medication has two remaining options: pay privately, or ask their employer. A great many are choosing the second, and the effect on benefit plans is now measurable.
What the Research Found
Research published in January by Howden Employee Benefits, part of the insurance intermediary group Howden, reports that one in four UK employees, 26%, has already used a weight-management drug. Some 41% believe their employer should cover these drugs as part of a healthcare plan.
The employer response has been rapid. According to the Changing Face of Employee Health report, 44% of employers are poised to rewrite their healthcare plans to meet the shift in what staff expect.
The striking part is what sits next to that figure. Some 88% of employers say they are happy with the return on investment from the plans they already have. They are not rebuilding because the existing arrangement failed. They are rebuilding because a category of cost appeared that their plans were never designed around.
The NHS Threshold Is Why This Lands on Employers
NICE’s guidance, published in December 2024 and last updated in September 2025, is precise about who qualifies. A BMI of at least 35 plus a weight-related comorbidity, with a lower threshold, usually reduced by 2.5, for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. Treatment is reviewed at six months, and if less than 5% of initial weight has been lost on the highest tolerated dose, continuation becomes a clinical judgement.
Where the criteria are met, the drug must be funded in the NHS in England if it is the most suitable option. Where they are not, the NHS is not the route.
That single design decision is what converts a clinical question into a benefits question. The population that wants these drugs is considerably larger than the population NICE has funded, and the difference does not disappear. It arrives in HR inboxes.
Two further details in the guidance matter to anyone budgeting for this. The first is that the recommendation carries a commercial access agreement, added when the guidance was last updated in September 2025 alongside a revision to the tirzepatide price list. NICE does not publish what the NHS pays under it; the guidance directs enquiries to NHS England’s commercial medicines team. An employer trying to work out whether its plan is being charged a reasonable rate therefore has no public benchmark to measure against, which is a recurring feature of health procurement in this country and one this desk has run into before, most recently across six NHS digital deals signed in four days without a single disclosed price.
The second is a grandfathering provision. NICE states the recommendations are not intended to affect treatment that had already begun in the NHS before the guidance was published, and that people being treated outside the current criteria may continue on their previous funding arrangements until they and their clinician judge it appropriate to stop. The practical result is a cohort of patients funded on terms that a new applicant with identical characteristics would not qualify for. That is a defensible piece of clinical continuity, but it also means the eligibility line is blurrier in practice than the printed threshold suggests, and employees comparing their situation with a colleague’s will not always be comparing like with like.
Half the Employers Covering Them Call It a Cost Concern
Among UK businesses that already cover weight-management drugs, 50% now view them as a cost concern that directly affects what else they can offer. Some 49% expect those costs to grow further, and one in five cite obesity-related conditions and their treatment as the single most prominent factor pushing their costs up.
Only 5% expect the pressure to ease from next year onwards. That is close to unanimity, and unanimity in a survey of cost expectations usually means the respondents can already see the invoices.
The trade-off inside a benefits budget is zero-sum in the short run. Money spent covering a new medication is money not spent on something else in the same plan, which is why 50% describing it as a cost concern is a statement about the rest of the package as much as about the drugs.
Medical Inflation at 7% Is the Wider Squeeze
Cheryl Brennan, managing director of Howden Employee Benefits UK, put a number on the backdrop: medical inflation is set to be 7%, which combined with general inflation leaves businesses facing price rises of more than 10% over the coming year.
“It is no longer a future projection,” she said of the financial impact of the new obesity medications. “It’s a current reality that is forcing business leaders to rethink their plan design and budget allocations.” She went further on scale, describing the rapidly increasing use of these drugs as “one of the biggest challenges to benefits affordability in decades”.
Double-digit renewal increases change behaviour regardless of what is driving them. An employer facing that arithmetic has three levers: pay more, cover less, or shift the mix toward things that reduce claims later. Most are reaching for the third.
The Prevention Argument, and Its Limits
Some 72% of UK businesses are already investing in prevention, and the case for treating weight-management drugs as part of that is not hard to make. Weight-related illness, diabetes among it, accounts for a meaningful share of sick days, and absence is a direct cost to output. The Office for National Statistics maintains the national picture in its annual sickness absence dataset, most recently released on 1 May 2026.
Brennan was careful not to oversell it. These drugs “should not be seen as a silver bullet for completely alleviating any issues and pressures caused by weight-related conditions”, she said, but rather “a component of broader, more personalised support”.
That caution is warranted by the timing problem. Prevention spending lands in this year’s budget and any saving lands in a later one, possibly after the employee has moved on. The employer pays for a benefit the labour market partly captures. It is the same structure that makes training spend chronically hard to justify inside a single company even when it is obviously worth doing across an economy.
Which Drugs Get Covered, and Why Not the Others
The governance problem is sharper than the budget one, and Brennan named it directly. “There remains plenty of drugs and treatments which are currently not covered by employers’ health plans,” she said. “So firms will need to justify why they chose to cover weight loss drugs ahead of others.”
That is the question most benefit committees have not yet had to answer in public. A plan that funds a weight-management drug for an employee below the NHS threshold, while not funding a treatment for a colleague with a different condition who is also outside NHS criteria, has made a choice about whose unmet need counts. Demand made the first choice; nothing in the survey suggests a principle was applied.
Employers deciding this are effectively setting a private clinical threshold, without the appraisal machinery NICE uses to set the public one.
What Employers Actually Have to Decide
Three things follow from the research, and none of them are optional.
The first is that demand is established rather than emerging. A quarter of employees have used one of these drugs already, so the plan is being designed after the behaviour, not before it.
The second is that the cost is structural. With medical inflation at 7% and only 5% of businesses expecting relief, this is not a spike to absorb for a year.
The third is that the government is simultaneously moving more health responsibility toward employers, as the shape of the Keep Britain Working framework makes plain. That arrives alongside the drug question rather than instead of it, and against a backdrop where economic inactivity through ill health already costs £212bn a year.
An employer can reasonably conclude that covering these drugs is worth it. What the research suggests is that most are reaching that conclusion under pressure from demand rather than from analysis, and that the justification will be asked for later.
About The Author
More Stories
Employer Health Cover Climbs 10% While Europe Averages 8%
John Ternus Begins at $4tn Where Cook Began at $350bn
Only 30% of CMOs Can Scale the AI Their Marketing Budgets Are Buying